# US 2025/0152537 A1 · Compositions and methods for the treatment of human immunodeficiency virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152537 A1
- Document ID: US20250152537A1
- Status: Published application
- Kind: A1
- Application number: 18/839,225
- Filed: 2023-02-15
- Published: 2025-05-15
- Earliest claimed: 2022-02-16
- Applicants: Prothione LLC
- Inventors: Laura LILE; Albert CRUM
- Web page: https://patentgrep.com/patent/US20250152537A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 31/12: Antivirals
- A23L 33/175: Amino acids
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

Compositions and methods for inhibiting human immunodeficiency viral infection and for treating subjects already infected with a human immunodeficiency virus such as HIV-1. The compositions and methods reduce HIV viral load in subjects infected with HIV.

## Claims

### Claim 1

A method for reducing viral load in a subject infected with a human immunodeficiency virus, the method comprising administering to the subject, on a daily basis and for at least three consecutive days, either one of the following:
about 2,355 mg glycine, about 2,355 mg L-glutamine, about 1,200 mg L-cystine, about 12 mg coenzyme Q10, and about 0.034 mg selenomethionine; or
about 1,177 mg glycine, about 1,177 mg L-glutamine, about 600 mg L-cystine, about 6 mg coenzyme Q10, and about 0.017 mg selenomethionine.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the about 2,355 mg glycine, about 2,355 mg L-glutamine, about 1,200 mg L-cystine, about 12 mg coenzyme Q10, and about 0.034 mg selenomethionine are administered, and wherein the subject is an adult human.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the subject is administered the about 2,355 mg glycine, about 2,355 mg L-glutamine, about 1,200 mg L-cystine, about 12 mg coenzyme Q10, and about 0.034 mg selenomethionine, or the about 1,177 mg glycine, about 1,177 mg L-glutamine, about 600 mg L-cystine, about 6 mg coenzyme Q10, and about 0.017 mg selenomethionine, for at least five consecutive days.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method according to claim 1, wherein the about 1,177 mg glycine, about 1,177 mg L-glutamine, about 600 mg L-cystine, about 6 mg coenzyme Q10, and about 0.017 mg selenomethionine are administered, and wherein the subject is a human of at least 3 years of age and weighing no more than about 40 kg

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method according to claim 1, wherein a composition comprises:
the about 2,355 mg glycine, about 2,355 mg L-glutamine, about 1,200 mg L-cystine, about 12 mg coenzyme Q10, and about 0.034 mg selenomethionine; or the about 1,177 mg glycine, about 1,177 mg L-glutamine, about 600 mg L-cystine, about 6 mg coenzyme Q10, and about 0.017 mg selenomethionine; and
wherein the administering comprises orally administering to the subject the composition once-daily or twice-daily for at least three consecutive days.

### Claim 8

(canceled)

### Claim 9 (depends on 7)

The method according to claim 7, wherein the composition comprises the about 1,177 mg glycine, about 1,177 mg L-glutamine, about 600 mg L-cystine, about 6 mg coenzyme Q10, and about 0.017 mg selenomethionine, and wherein the subject is a human of at least 3 years of age and weighing no more than about 40 kg.

### Claim 10

A method of preventing a human immunodeficiency virus infection in a subject, the method comprising orally administering to the subject a composition either one of the following:
about 2,355 mg glycine, about 2,355 mg L-glutamine, about 1,200 mg L-cystine, about 12 mg coenzyme Q10, and about 0.034 mg selenomethionine; or
about 1,177 mg glycine, about 1,177 mg 1a-glutamine, about 600 mg L-cystine, about 6 mg coenzyme Q10, and about 0.017 mg selenomethionine.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the human immunodeficiency virus is HIV-1.

### Claim 12

Use of glycine, L-glutamine, L-cystine, coenzyme Q10, and selenomethionine in the preparation of a medicament for treating HIV-1 infection in a subject.

### Claim 13

(canceled)

### Claim 14 (depends on 7)

The method according to claim 7, wherein the composition comprises the about 2,355 mg glycine, about 2,355 mg L-glutamine, about 1,200 mg L-cystine, about 12 mg coenzyme Q10, and about 0.034 mg selenomethionine, and wherein the subject is an adult human.

### Claim 15 (depends on 7)

The method according to claim 7, wherein the composition is administered for at least five consecutive days.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the composition comprises the about 2,355 mg glycine, about 2,355 mg L-glutamine, about 1,200 mg L-cystine, about 12 mg coenzyme Q10, and about 0.034 mg selenomethionine, and wherein the subject is an adult human.

### Claim 17 (depends on 10)

The method according to claim 10, wherein the composition comprises the about 1,177 mg glycine, about 1,177 mg L-glutamine, about 600 mg L-cystine, about 6 mg coenzyme Q10, and about 0.017 mg selenomethionine, and wherein the subject is a human of at least 3 years of age and weighing no more than about 40 kg.

### Claim 18 (depends on 10)

The method according to claim 10, wherein the composition is administered to the subject once-daily or twice daily, for at least three consecutive days.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the composition is administered for at least five consecutive days.
